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Because cell turnover occurs in all adult organs, stem/progenitor cells within the stem-cell niche of each tissue must be
appropriately mobilized and diﬀerentiated to maintain normal organ structure and function. Tissue injury increases the demands
on this process, and thus may unmask defective regulation of pathways, such as Hedgehog (Hh), that modulate progenitor cell
fate. Hh pathway dysregulation has been demonstrated in many types of cancer, including pancreatic and liver cancers, in which
defective Hh signaling has been linked to outgrowth of Hh-responsive cancer stem-initiating cells and stromal elements. Hence,
the Hh pathway might be a therapeutic target in such tumors.
1.Introduction
The cancer stem cell hypothesis assumes that cancers
originate from mutated tissue stem cells (SCs) that have
dysregulated self-renewal properties, and thus selectively
drive tumor growth. Current chemotherapeutic agents and
radiation therapy target the rapidly dividing cells that form
the bulk of the tumor but do not target the relatively qui-
escent cancer stem cell (CSC), thus possibly accounting for
treatment failures. Furthermore, both SCs and CSCs appear
to have multidrug resistance, antiapoptotic machinery, and
enhanced DNA repair allowing them to evade conventional
treatments [1–4]. Thus, to target tumors eﬀectively and
with minimal toxicity, drugs need to be identiﬁed that
speciﬁcally target the relatively rare CSC population while
sparing normal tissue stem cells.
2.Biologic Propertiesof CancerStemCells
The properties that CSCs are postulated to exhibit are:
(1)tumorigenic capacity or self-renewal, (2)the potential for
multilineage diﬀerentiation (such that they can recapitulate
the multiple tumor cell types found in the parent tumor),
(3)serial passage, and (4)expression of a unique repertoire
of surface markers that allow for their reliable identiﬁcation
and puriﬁcation [5]. Speciﬁcally, the CSC hypothesis posits
that within a given tumor, only a distinct phenotypic subset
of cells has tumorigenic capacity, that is, injection of this
cell fraction into nude mice is able to fully recapitulate the
parent tumor. Currently, serial passage in xenotransplanta-
tion models is the gold standard assay for deﬁning the CSC
fraction [6].
Normal tissue SCs tightly regulate the balance between
self-renewal and diﬀerentiation, and quiescence and prolif-
eration (reviewed in [7, 8]). SC number, in the context of the
stem cell niche, is precisely maintained via the ratio of sym-
metric and asymmetric cell divisions. Dysregulation of self-
renewal pathways appears to result in CSC overpopulation
[9,10].Thismaybeduetoanincreaseinsymmetricdivisions
oftheCSCandmayrepresentapotentialdrugtarget[11,12].
As has been well characterized in the hematopoietic
system, the cells within solid organs appear to demonstrate a
hierarchy in which stem cells give rise to committed progen-
itor cells which give rise to rapidly proliferating cells which
give rise to terminally diﬀerentiated cells. As SCs mature
from a self-renewable stem cell to a terminally diﬀerentiated
cell, they progressively lose their ability for self-renewal and
pluripotency but gain mitotic activity. By analogy to normal2 Journal of Oncology
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cell types that comprise a given tumor, lending credence to
the idea that tumors can be viewed as aberrantly functioning
complexorgans. Tumorheterogeneityislikelya consequence
of ongoing accumulation of mutations over time that result
in variable degrees of cellular diﬀerentiation.
3.Dysregulationof Self-RenewalPathwaysin
CSCs:HedgehogPathwayInvolvement
Mutations in fundamental self-renewal pathways, such as
the Hh pathway, likely cause normal stem cells to become
independent of regulatory signals that are generated by
their microenvironment. These pathways play a critical role
in development and are usurped by transformed cells for
tumor initiation, progression, and metastasis. The hedgehog
proteins are secreted signaling proteins that were initially
identiﬁed in Drosophila as segment polarity genes. In mul-
tiple tissue types, the Hh pathway plays a key role in organo-
genesis, patterning, and stem cell maintenance. Depending
upon context, Hh can function both as a morphogen and
a mitogen. As a morphogen, Hh induces cell diﬀerentiation
in a concentration-dependent manner. As a mitogen, it
drives the proliferation of precursor cells and mediates
the interaction between the epithelial and mesenchymal
compartments [13]. In multiple tissue types, it has been
demonstrated that mesenchymal cells and progenitor cells
are Hh responsive. In contrast, mature epithelial cells are
typically nonresponsive to Hh.
The components of the Hh signal transduction machin-
eryhavebeenelucidated,andwhiletherearesomeimportant
diﬀerences across species, the pathway remains relatively
well conserved between Drosophila and higher organisms.
Three secreted Hh ligands have been identiﬁed in humans,
Sonic hedgehog (Shh), Indian hedgehog (Ihh), and Desert
h e d g e h o g( D h h )a n da r ek n o w nt os i g n a li na na u t o c r i n e
and paracrine manner. In the absence of Hh ligand,
Patch (PTCH), the hedgehog receptor binds and inhibits
Smoothened (SMO) and thus prevents target gene tran-
scription. Binding of the Hh ligand to PTCH releases SMO
and allows for further propagation of the signal, leading
to target gene transcription through three Gli transcription
factors, Gli1, Gli2, and Gli3. Gli proteins regulate target gene
expression by direct association with a consensus sequence
located within the promoter ofthe target genes. Thus, PTCH
is a negative regulator and SMO a positive regulator of
the pathway [14]. Intriguingly, in mammals, it appears that
protein components of the primary cilium are required for
the coordination of hedgehog signaling [15, 16].
Loss of function mutations in the Hh receptor, PTCH,
were initially noted in patients with Gorlin syndrome or
basal cell nevus syndrome [17, 18]. Gorlin patients have
a variety of developmental defects and have an increased
incidence of benign and malignant tumors including basal
cellcarcinomas(BCC),medulloblastomas,ovarian ﬁbromas,
rhabdomyosarcomas, and meningiomas. A large majority of
sporadic medulloblastomas and basal cell carcinomas also
exhibit hyperactive Hh signaling (in a ligand-independent
fashion) due to mutations in Hh pathway components
including, PTCH, SMO, and occasionally Suppressor of
Fused (SUFU), a negative regulator of the Hh pathway
[19]. In clinical trials, SMO inhibitors have now been
demonstrated to have potent antitumor activity in patients
with BCC and one patient with medulloblastoma, thus con-
ﬁrmingan“oncogeneaddiction”modelinwhichderegulated
Hh signaling results in increased cell proliferation and tumor
formation [20, 21].
There is now a growing body of evidence that the Hh
pathway is activated in a variety of other solid tumors
including colorectal, pancreatic, breast, and small cell lung
cancer and hepatocellular carcinoma [22–28]. Unlike BCC
and medulloblastoma, Hh activation in these tumor types is
not mutation driven. Both in vitro and in vivo, Hh pathway
activationappearstoimpacttumorprogressionviaeﬀectson
cell proliferation, cell survival, angiogenesis, invasion, and
genetic instability. Given that this data has been reviewed
recently and comprehensively [14, 19, 29], we will focus
on the role of Hh signaling in cancer stem cell expansion
and maintenance with a focus on pancreatic cancer and
hepatocellular carcinoma (HCC).
Increased Hh pathway activity was ﬁrst documented in
early pancreatic cancer by Thayer et al. where the degree
of Shh expression in the ductal epithelium was noted
to positively correlate with degree of atypia [23]. While
Shh expression appeared to be conﬁned to the epithelium,
increased PTCHexpression wasseenintheabnormal epithe-
lium and the surrounding mesenchymal cells suggesting
both an autocrine and paracrine mechanism of signaling.
Furthermore, treatment of pancreatic cancer cells lines with
the SMO inhibitor, cyclopamine, resulted in decreased cell
proliferation and increased apoptosis further supporting
autocrine signaling. In vivo, cyclopamine treatment of
pancreatic tumor xenografts resulted in decreased tumor
mass suggesting an important role for Hh signaling in cell
survival and proliferation.
A series of experiments that have been performed to fur-
ther deﬁne an epithelial versus stromal role for Hh signaling
have led to contradictory results. Yauch et al. demonstrated
that in both colon and pancreatic adenocarcinomas, epithe-
lialtumorcellssecretehighlevelsofHhligandincomparison
to normal tissue controls. Hh pathway activation is noted in
the neighboring stromal cells but not in the epithelial cells
consistent with a paracrine signaling mechanism [30]. In
addition, expression of an oncogenic allele of SMO in the
pancreatic epithelium did not result in Hh pathway activa-
tion and had no impact on the development of pancreatic
neoplasia, while SMO activation in the mesenchyme led to
Hh pathway activation. Taken together, these data suggest
that only the stromal compartment is competent to activate
Hh signaling [31]. While this data is consistent with Hh
signaling in CSCs,which donot express markers of epithelial
diﬀerentiation, these results conﬂict with considerable evi-
dence for ligand-dependent Hh-signaling in epithelial cells
of multiple other tumor types [32]. These discrepancies may
be explained in part by diﬀering mouse models, human
tumor xenografts versus transgenic models of spontaneous
carcinomas. Clearly, further study is required to deﬁne theJournal of Oncology 3
precise mode of Hh signaling, as it will have important
ramiﬁcations for drug development.
In order to determine whether increased Hh activity
is a property of all pancreatic tumor cells or is selective
for the CSC, Li et al. demonstrated, using quantitative real
time-pcr, that Shh transcripts were 4-fold upregulated in the
bulk pancreatic xenograft cells and 43-fold upregulated in
the CD44+CD24+ESA+ pancreatic CSC as compared with
normal pancreatic epithelial cells [33]. Active Hh signaling
has now also been identiﬁed in the CSCs from glioblastoma
and breast tumors and modulation of Hh pathway activity
in these cell types results in decreased tumorigenic potential
and depletion of the CSC compartment [34–36].
4.TissueInjuryand Repair:
APotentialSourceofCSCs
In development,both the pancreas and the liver are speciﬁed
by domains of the gut endoderm. Embryonic outgrowths
of the dorsal and ventral regions of the foregut endoderm
g i v er i s et ot h ee n d o c r i n ea n de x o c r i n ep a n c r e a s .T h el i v e r ,
however, derives solely from the ventral foregut endoderm
[37, 38]. Using embryo tissue explant assays, it has been
shown that the default fate of the ventral endoderm is
to activate the pancreatic organogenesis program. In the
developing embryo, the ventral foregut becomes closely
apposed to the cardiac mesoderm, and this proximity is
required for liver speciﬁcation [38]. FGF signaling from
the cardiac mesoderm induces the local production of
sonic hedgehog, and BMP signaling from the underlying
septum transversum mesenchyme cells coordinately directs
the development of the liver bud and inhibits pancreas
development.Conversely, treatment with the BMP inhibitor,
noggin, enhances pancreatic gene expression and suppresses
hepatic gene expression in ventral foregut explants [39,
40]. These multiple signaling pathways direct endoderm
patterningviainductionofspeciﬁctranscription factors. The
Forkhead Box A proteins (Foxa) are transcription factors
expressed in endoderm derived tissues and are required
for hepatic, pancreatic, and pulmonary speciﬁcation [41].
Transcriptionalactivation offoxa2isdirectlyregulatedbythe
hedgehog target genes, gli proteins [42], providing support
for its central role in hepatic organogenesis. The liver bud
then gives rise to cells destined to become bipotential liver
progenitor cells, or hepatoblasts, which give rise to two
distinct lineages, hepatocytes and cholangiocytes [41].
A comparison of pluripotent, murine embryonic stem
(ES) cells, endodermally lineage-restricted ES cells, and
mature hepatocytes suggests that hedgehog activity is pro-
gressively silenced as progenitors diﬀerentiate into mature
liver parenchymal cells [43]. Treatment of hepatic progen-
itors isolated from human livers (EpCAM+ cell fraction)
with cyclopamine results in increased cellular necrosis and
apoptosis, demonstrating that Hh activity is required for
optimal viability of the progenitor cells. While minimal Hh
ligand production is seen in healthy, human hepatocytes,
the small resident progenitor population within the normal
adult liver, residing along the canals of Hering, continues to
demonstrate expression of Hh ligands, and Hh-responsive
target genes [44, 45].
Hh signaling is reactivated in the liver after acute or
chronic liver injury when major reconstruction of the adult
liver is required. Moreover, the degree of hepatic production
of Hh ligands and accumulation of Hh responsive cells is
typically proportionate with the severity of liver damage and
ﬁbrosis. Immunohistochemical analysis of diseased human
livers, such as those from patient with chronic viral hepatitis
[46], alcoholic liver disease [47], and nonalcoholic fatty liver
disease [44, 48], conﬁrms that Hh signaling and the number
of Hh responsive cells is increased in the presence of injury.
The Hh-responsive cells are noted in the expanded progeni-
torandstromalcellcompartments, suggestingthatthesecells
actively contribute to regenerative processes in adult livers.
This was conﬁrmed by treating healthy, adult mice with
cyclopamine after 70% partial hepatectomy, which provides
atremendousregenerativepressure.Incomparisontovehicle
control, inhibition of Hh signaling after partial hepatectomy
prevented normal liver regeneration by blocking progenitor
expansion and ﬁbrogenic liver repair. Notably, cyclopamine-
treated animals were unable to reconstitute their liver mass,
and there was signiﬁcant mortality in the group 48-hours
postpartial hepatectomy in comparison to vehicle treated
controls [49]. Furthermore, in rodent models of liver injury,
once the oﬀending agent is removed, Hh ligand levels
decline and Hh-responsive cells gradually regress as normal
l i v e ra r c h i t e c t u r ei sr e s t o r e d[ 50, 51]. Taken together, these
data suggest that in the setting of acute injury, transient
activation of the Hh pathway is necessary for eﬀective
regeneration of the adult liver (Figure 1). However, chronic
or persistent injury results in prolonged increases in Hh
signaling, thus perpetuating the expansion of myoﬁbroblasts
and liver progenitor cells which contribute to ﬁbrotic repair
or cirrhosis.
This data has signiﬁcant implications for the develop-
ment of HCC as cirrhosis is the most important determi-
nant of risk for the development of HCC. Hh signaling
activates prosurvival pathways in several types of liver cells
including malignant hepatocytes. Expression of Shh is noted
in approximately 60% of HCCs and expression of the Hh
target genes, Gli1 and PTCH, was noted in 50% of tumors
suggesting that the Hh pathway is activated in HCC. In
three HCC cell lines, Hep3B, Huh7, and PLC/PRF/5, with
detectable expression of Hh target genes, treatment with
Hh neutralizing antibodies or cyclopamine resulted in cell
growth inhibition and apoptosis. No eﬀects on cell viability
were noted in the two HCC cell lines that lacked Hh
signaling, demonstrating that the results were speciﬁc to the
Hh pathway [27, 28].
In multiple tissue types, Wnt pathway activity is also
crucial to the maintenance of the stem cell compartment and
a complex interaction of Wnt, Notch, Hedgehog, and Bmp
signaling regulatesthebalancebetween stemcellrenewaland
cellulardiﬀerentiation[52, 53].While therole ofWnt signal-
ing in liver SCs remains poorly understood, prior work in a
mouse model of chronic liver injury has demonstrated that
Wnt ligand induction is localized to postnatal hepatic pro-
genitors both in vitro and in vivo [54]. Abnormal regulation4 Journal of Oncology
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Figure 1: Healthy adult livers exhibit little hedgehog activity. In the presence of liver injury, hepatocytes are subject to cellular stress and in
some cases undergo apoptosis. In this setting of injury, hedgehog ligand production increases resulting in the appropriate expansion and
diﬀerentiation of progenitor cells allowing for liver reconstruction. As the insult is removed, Hh pathway activity slowly declines, and the
progenitor population gradually dwindles away with recovery of liver health.
of the Wnt signaling pathway has been extensively described
as a key early carcinogenic event in HCC development.
Multiple groups have demonstrated that HCCs harbor acti-
vating mutations of β-catenin, a transcription factor in Wnt
signaling, or inactivating mutations of AXIN1 and AXIN2,
negative regulators of this pathway [55–60]. Furthermore,
treatment with anti-Wnt-1 antibodies dose dependently
inhibits the viability and proliferation of Wnt-1 overex-
pressing HCC cell lines, Huh7 and Hep40, but not normal
hepatocytes. Intratumoral injection of anti-Wnt-1 antibody
also suppresses tumorgrowth in a Huh7 xenograft model via
induction of tumor cell apoptosis [61]. Further studies will
be required to clarify the role of Wnt signaling in liver CSCs.
Taken together, these data suggest that stem cell renewal
pathways such as Hh and Wnt are upregulated in the
setting of chronic liver injury and result in the expansion of
liver progenitor populations. Ongoing production of ligand
confers a survival advantage to these immature cells, some
of which may eventually become tumor-initiating cells for
primary liver cancers [62, 63]. This model of cancer in
which neoplasia is the result of overexuberant tissue repair
is supported by the strong association between chronic
tissue injury and cancer incidence [64]. This association is
particularly robust in hepatobiliary cancers, where exposure
to a variety of toxins [65, 66], chronic infections [46, 67, 68],
and inﬂammatory conditions [69, 70] signiﬁcantly increases
cancer risk. In the setting of ongoing injury, expansion of
the progenitor pool persists allowing for the accumulation
of genetic or epigenetic events that constitutively activate the
stem/progenitor cell compartment, thus resulting in tumor
initiation (Figure 2).
Investigators have now identiﬁed multiple markers that
have been used to successfully enrich the CSC fraction
from HCCs [52, 71, 72]. Genetic alterations in self renewal
and pluripotency pathways, including Wnt/β-catenin [73],
Notch [74], Hh [74], myc [75], and TGF-β [52], have
been documented in these cells. Furthermore, epigenetic
changes including alterations in DNA methylation patterns
[76] and the aberrant expression of both oncogenic [77, 78]
and tumor suppressive [79] microRNAs have been shown
to contribute to hepatocarcinogenesis. These results beg
the question: would targeting the tissue SC be an eﬀective
chemoprevention strategy?
5.MultipleRolesofCancerStemCells:
PancreaticCancerasaModel
Ontologically, a stem cell-like cell is an ideal target for
transformation due to their capacity for self-renewal and
long life. Pathways such as Hedgehog, Notch, and WNTJournal of Oncology 5
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Figure 2: In the presence of continued liver injury, there is ongoing upregulation of the Hh pathway and persistent expansion of the
progenitor pool. Thus, there is an increased probability for the accumulation of genetic or epigenetic events in the tissue stem cells resulting
in oncogenic transformationto a cancer stem cell, and ultimately leading to tumor initiation.
have well established roles in organogenesis and normal
stem cell renewal (reviewed in [13, 80, 81]). Growing
evidence suggests that these pathways are dysregulated in
transformation and thus contribute to tumor initiation,
tumor maintenance, and metastasis of multiple tumor types
[22, 23, 82–86]. Furthermore, as a consequence of self-
renewal, stem cells persist for long periods of time, likely
allowing them to accumulate the numerous mutations
necessary fortransformation [87].Buttheultimateoriginsof
CSCs remain controversial at this time. Whether CSCs arise
from existing tissue stem cells, restricted progenitor cells, or
from mutations in terminally diﬀerentiated cells, resulting
in dediﬀerentiation likely depends on context (reviewed in
[8, 88]). Nonetheless, each of these scenarios is consistent
with the idea that distinct population of cells with stem cell
properties is essential for the development and perpetuation
of various human cancers.
Utilizing a xenograft model of primary pancreatic
adenocarcinoma, Li et al. puriﬁed a subpopulation of
CD44+CD24+ESA+ pancreatic cancer cells (approximately
0.2%–0.8% of the total cell number) that demonstrated
the requisite CSC properties of self-renewal, tumorigenic
capacity, and production of phenotypically diverse progeny
[33]. Combinatorial approaches demonstrated that the cells
expressing all three markers had the highest tumorigenic
potential, and the percentage of cells expressing all three
markers remained constant with serial passage. These three
markers have been previously used to mark CSCs in other
tumor types and are known to act as cell adhesion molecules
with multiple signaling functions (reviewed in [6]).
However, the role of CSCs may not be conﬁned to tumor
initiation and growth, but may also play a role in metastases.
Previous studies had demonstrated that in colon cancer
and brain tumors, CD133+ marks the CSC population [9,
10, 89]. Hermann et al. demonstrated that the tumorigenic
potential of pancreatic cancer is restricted to CD133+ cells,
as they recapitulate the original tumor when injected into
athymic mice [90]. In addition, they identiﬁed a subpopula-
tionofCD133+CXCR4+pancreaticcancercellsfromhuman
pancreatic cancer tissue samples that localized almost exclu-
sivelytotheinvasivefrontofthetumor.Postulatingthatthese
cells played a role in metastatic potential, CD133+CXCR4+
cells and CD133+CXCR4− cells were orthotopically injected
into athymic mice. While both groups of animals evidenced
localized tumor development, only mice in the CXCR4+
group demonstrated liver metastases, suggesting an impor-
tantroleforCD133+CXCR4+pancreaticCSCsinmetastasis
formation. This study suggests two forms of cancer stem
cells, a localized form and a migratory form. Notably,inhibi-
tion of CXCR4 (via both drug and neutralizing antibody) in
this tumor model prevented metastatic disease. This ﬁnding
may have important clinical implications.
At this point, it remains unclear whether there is
more than one population of CSCs in pancreatic cancer6 Journal of Oncology
or the diﬀering results are due to methodological issues.
Interestingly, there does appear to be some degree of overlap
betweenCD44+CD24+ESA+andCD133+pancreaticcancer
cells [90] .W h i l en o n eo fa b o v em a r k e r sa p p e a rt os e l e c t i v e l y
characterize a pure population of CSCs, the studies taken
together do provide consistent evidence for an enriched
CSC population (reviewed in [91]). However, whether
CSCs are the only cells with tumorigenic potential remains
controversial [92, 93].
6.EMT Confersa StemCellPhenotype and
aMetastaticPhenotype
Consistent with the data presented above, CSCs appear
to undergo adaptive changes over time as programs are
activated that foster invasion and migration. Epithelial-
mesenchymal transition (EMT) and the reverse process
mesenchymal-epithelial transition (MET) play central roles
in organogenesis, and in the context of tumorigenesis,
appear to confer CSC properties and drive tumor metastasis
(reviewed in [88, 94]). Conventionally, epithelial cells are
deﬁned as tightly adherent cells with apical-basal polarity
that are organized in adherent sheets via adherens junctions,
tight junctions and desmosomes. Typically, epithelial cells
are surface barrier cells with secretory functions and remain
separated from adjacent tissues by a basal lamina. In
contrast,mesenchymal orstromal cellsare loosely organized,
nonpolarized, migratory cells embedded within extracellular
matrix and form the connective tissue or stroma of a given
organ. The conversion of epithelial cells to mesenchymal
cells involves profound morphological changes including
dissolution of cell adhesions, loss of apicobasal polarity
and acquisition of migratory and invasive phenotypes. This
process appears to be coopted by transformed cells during
tumor progression, and interestingly, results in expression of
stem-cell markers.
Mani et al. reported that induction of EMT, via ectopic
expression of the transcription factors Twist or Snail in
immortalized human mammary epithelial cells, leads to
acquisition of mesenchymal traits, expression of stem cell
markers, and an increased ability to form mammospheres,
a property associated with epithelial stem cells [95]. Prior
to EMT, these cells express the CD44low/CD24high phenotype
on the cell surface, corresponding to the phenotype of the
majority of cells found in breast carcinomas. Following
induction of EMT, the cells undergo conversion to the
CD44high/CD24low conﬁguration, a proﬁle that is associated
with human breast CSCs and normal mammary epithelial
stem cells [96]. Injection of the transformed human mam-
mary epithelial cells that have undergone EMT into immun-
odeﬁcient hosts results in signiﬁcantly increased tumor
formation in comparison to cells lacking either Twist or
Snail expression. Morel et al. further extended these ﬁndings
by noting that activation of the Ras signaling pathway
appears to be a crucial event in facilitating the emergence
of CD24low cells [97]. Furthermore, microarray analysis
of poorly diﬀerentiated human tumors associated with an
aggressive clinical course were noted to have preferential
overexpression of genes normally expressed by ES cells,
thus conﬁrming “stemness” as a predictor of poor clinical
outcome [98]. Taken together, these ﬁndings convincingly
demonstrate a link betweenEMT and the acquisitionofstem
cell properties.
There is a considerable body of in vitro and in vivo
evidence that EMT is centrally involved in the process of
metastasis (reviewed in [88, 94]). EMT has been noted to
occur at the invasive front of multiple diﬀerent cancer types
including colon carcinoma, breast carcinoma, and papillary
thyroid cancers [99–103] .T h ei n v a s i v ef r o n to ft h et u m o r
represents the host-tumor interface and EMT at this border
reﬂects the balance of growth pressures by the tumor body
andthetumorperiphery.Microarray signaturesofEMThave
been shown to correlate with aggressive histopathological
subtypes of human tumors and inducers of EMT such as
SNAIL1, SNAIL2, FOXC, and ZEB1 have been shown to
correlate with increased rates of disease relapse and poor
overall survival [101, 104–108]. In order to integrate the
concepts of CSCs and EMT, Brabletz et al. propose the
existence of two cancer stem cell populations, a stationary
cancer stem cell and a migratory cancer stem cell, in order to
modelallaspectsoftumorprogression[109].Thismodelhas
now been preliminarily validated in pancreatic cancer with
the identiﬁcation of two distinct populations of CSCs [90].
In order to carefully dissect the contribution of epithelial
and mesenchymal states to liver CSC growth and metastasis,
Ding etal. established an EMT modeloflivercancer. Asingle
CD133+, CD45− liver CSC puriﬁed from PTENloxp/loxp/Alb-
Cre+ mice was expanded and then sequentially transplanted.
This population of CSCs have been previously shown to
initiate HCC-like and cholangiocarcinoma-like tumors in
vivo [110]. With serial rounds of transplantation, two cell
populations became apparent; one with epithelial morphol-
ogy and a second with mesenchymal morphology. Clones
of these two cell populations were subisolated and PTEN
loss was conﬁrmed, demonstrating that tumor cells were
derived from the original PTEN−/− host. Subcutaneous
implantation of these cells into nude mice revealed that
the mesenchymal subpopulation of cells generated signif-
icantly larger tumors than those seen with the epithelial
subpopulation or the mixed cell population. Histologically,
epithelial cells generated hepatoma like tumors, while the
mesenchymal cells formed ﬁbroblastoma-like tumors. The
mixed cells formed tumors with both mesenchymal and
epithelial cell morphology. Furthermore, in vitro mesenchy-
mal cells were more migratory and invasive than their
epithelial counterparts and this was conﬁrmed in vivo by
demonstrating their increased metastatic capacity [111].
7.TargetingCancerStemCellsvia
HedgehogPathwayInhibition
Normal tissue stem cells and CSCs exhibit properties of
chemoresistance and radiation-resistance due to their rela-
tive quiescence, expression of ATP-binding cassette (ABC)
transporters, activated DNA repair systems, and resistance
to apoptosis [3]. A growing body of work now supportsJournal of Oncology 7
the idea that chemoradiotherapy spares or even enriches
the CSC population within the original tumor, allowing
these cells to repopulate the recurrent tumor, despite the
fact that the bulk of the tumor has disappeared. In vitro,
the CD133+ pancreatic cancer stem cells exhibit signiﬁcant
drug resistance to the chemotherapy agent gemcitabine in
comparison to autologous CD133− cells. In vivo, treatment
of pancreatic xenografts with gemcitabine also resulted in
a signiﬁcant decrease in tumor volume, but an enrichment
of the CD133+ cell fraction, suggesting that CSCs play a
role in treatment resistance [90]. Similarly ionizing radi-
ation therapy of human glioma xenografts resulted in an
enrichment of the CD133+ glioma CSC subpopulation by
fourfold in comparison to untreated controls. Decreased
rates of apoptosis, preferential activation of DNA damage
checkpoint responses, more eﬃcient repair of DNA damage,
and activation of the stem cell renewal pathway, Notch, are
some of the mechanisms that underlie the increased survival
of CD133+ glioma cells. Pharmacological inhibition of the
Chk1 and Chk2 checkpoint kinases as well as the Notch
pathway (by gamma-secretase inhibitors) has been shown
to overcome the radioresistance of CD133+ glioma cells,
suggesting possible therapeutic targets [112, 113].
These observationsraisethequestionofwhethertheCSC
represents a new and viable therapeutic target. Some of the
most promising therapeutic strategies inhibit SC renewal
pathways,suchastheHhpathway,oftenincombinationwith
conventional cytotoxic agents. The role of hedgehog signal-
ing in pancreatic cancer metastases was investigated by Feld-
mann et al. using a spontaneously metastasizing xenograft
model of pancreatic cancer. These studies demonstrated that
while cyclopamine treatment did not signiﬁcantly inhibit
primary tumor growth, rates of distant metastasis to the
lung and liver were signiﬁcantly inhibited by cyclopamine
treatment and completely abolished by the combination of
gemcitabine and cyclopamine [114]. No histologic distinc-
tions in the tumortissue were detectedbetween cyclopamine
and vehicle-treated animals, but cyclopamine treatment did
result in a 3-fold reduction of ALDH-expressing pancreatic
cancer cells in vitro. ALDH has been implicated as another
putative marker of pancreatic CSCs, and this initial study
suggests that inhibition of the hedgehog pathway results
in depletion of the pancreatic CSC compartment and is a
putative mechanism for metastasis.
Mueller et al. further extended these ﬁndings by demon-
strating that dual inhibition of the hedgehog pathway
and the mTOR pathway in combination with gemcitabine
is required to completely eliminates both CD133+ and
CD24+CD44+EpCAM+ pancreatic CSC populations in
vitro.Incontrast,inhibitionoftheHhpathwayaloneincom-
bination with gemcitabine abolished the CD133+CXCR4+
migratory CSC population. Similarly, in a mouse model of
orthotopic pancreatic cancer, treatment with cyclopamine,
rapamycin (mTOR inhibitor) and gemcitabine was required
to fully inhibit growth at the primary site and resulted in a
signiﬁcant overall survival beneﬁt. However, treatment with
cyclopamine and gemcitabine resulted in complete inhibi-
tion of metastatic activity [115]. Thus, they conclude that
dual pathway inhibition is required for complete abrogation
of tumorigenic potential. Recently, Olive et al. utilized a
mouse model of gemcitabine-refractory, pancreatic ductal
adenocarcinoma to demonstrate that treatment with the
smoothenedinhibitor, IPI-926,aloneorincombinationwith
gemcitabine, results in depletion of the desmoplastic stroma
and an increase in intratumoral vascular density. In these
animals, concentrations of gemcitabine metabolites were
augmented by 60% following a ten day pretreatment with
IPI-926/gemcitabine. Furthermore, treatment with IPI-926
and gemcitabine (as opposed to either agent alone) resulted
in a transient reduction in tumor size at the primary site and
signiﬁcantly inhibited livermetastases, resulting in an overall
survival beneﬁt [83]. Their interpretation of these results is
that inhibition of the Hh pathway results in increased tumor
angiogenesis and stromal collapse, both contributing to
enhanced gemcitabine delivery to the pancreatic ductal cells.
However, an alternate explanation for these ﬁndings is that
Hh inhibition depletes the cancer stem cell compartment.
8.Conclusions
Cell turnover occurs in all adult organs. Hence, mainte-
nance of normal organ structure and function necessitates
appropriate mobilization and diﬀerentiation of cells within
the stem cell niche of each tissue. Demands on this process
increase duringadulttissue injuryand mayunmask defective
regulation of pathways, such as Hh and other morphogens
that modulate progenitor cell fate. Dysregulation of the Hh
pathway has been demonstrated in many types of cancer,
including pancreatic and liver cancers. In such tumors,
defective Hh signaling has been linked to outgrowth of Hh-
responsive cancer stem-initiating cells and stromal elements,
suggestingthattheHhpathwaymightbeatherapeutictarget.
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